Frequently Asked Questions
Below are some of the most frequently asked questions about Syneron. If you don't find what you're looking for here, please contact us directly.
A: Syneron Medical Ltd. manufactures and distributes medical aesthetic devices that are powered by its proprietary, patented combined-energy technology of bi-polar Radio Frequency (RF) and optical energy (either laser or light).
A: Syneron trades on NASDAQ under the ticker symbol ELOS.
A: Syneron was incorporated in the state of Israel in July of 2000.
A: Syneron’s initial public offering (IPO) was completed August 6, 2004. The company sold a total of 5,500,000 shares in the underwritten offering at $12.00 per share, raising $60 million.
A: Syneron announced a secondary offering on March 9, 2005. The company sold a total of Syneron 7,000,000 secondary shares held by employees, directors, and founders at $28.00 per share.
A: Syneron’s principal executive offices are located at:
Tavor Building 4,
P.O. Box 550
Yokneam Illit 20692
Syneron’s primary North American office is located at:
3 Goodyear, Suite A
IRVINE, CA 92618
Syneron has offices and distributors throughout the world which provide service and support, including Asian headquarters in Hong Kong.
A: Syneron operates on a December 31 fiscal year end.
A: Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, is Syneron’s auditor.
A: To view a complete list with biographies, click on the Directors and Management links in the Investor Relations section of the Company’s Web site at www.syneron.com.
A: The Company’s transfer agent is American Stock Transfer and Trust Company.
American Stock Transfer and Trust Company
59 Maiden Lane
New York, New York 10038
Toll free: 866-668-6550
A: Syneron does not currently pay a dividend on its common stock.
A: Syneron does not currently offer a direct stock purchase plan.
A: Syneron’s CUSIP number is M87245102.
A: Please visit the Investor Relations page on the Company Web site. A message box is provided in which individual questions can be asked.
A: To be placed on the Company’s e-mail news distribution list, please visit the Email Alerts link in the Investor Relations section of the Company Web site.
A: A complete list of covering analysts can be found by clicking on the Analysts link.
A: Syneron files periodic reports with the SEC, including:
· Annual Report on Form 20-F
· Quarterly Reports on Form 6-K, incorporating:
o Quarterly Earnings Results
o Proxy Statement
o Annual Report to Shareholders
These filings can be obtained from the SEC Filings link on the Investor Relations section of the Company Web site or by visiting www.sec.gov.
A: Syneron’s upcoming events can be found by clicking on the Calendar link on the Investor Relations page of the Company’s Web site.
Open to review the merger FAQs